In the PRODIGE 24/CCTG PA.6 trial, which adjuvant regimen demonstrated superior disease-free and overall survival compared to gemcitabine alone after R0/R1 resection of pancreatic ductal adenocarcinoma?

• A Gemcitabine + nab-paclitaxel
• B Capecitabine monotherapy
• C Erlotinib + gemcitabine
• D Modified FOLFIRINOX (mFOLFIRINOX) ✓

Explanation

The PRODIGE 24 trial showed adjuvant modified FOLFIRINOX (oxaliplatin + irinotecan + leucovorin + fluorouracil with reduced irinotecan) achieved median OS of 54.4 months versus 35 months for gemcitabine alone after curative resection of pancreatic cancer — an unprecedented improvement. Capecitabine (ESPAC-4 trial) is an alternative but less potent option. mFOLFIRINOX is now the preferred regimen for fit patients.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.